[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Hamid AR, Umbas R: Metastasis of testicular carcinoma in the inguinal region. Acta Med Indones; 2009 Jan;41(1):25-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of testicular carcinoma in the inguinal region.
  • A standard protocol for the management of inguinal metastasis from testicular cancer still has not yet been established.
  • Metastasis of testicular cancer to inguinal lymph node rarely occurs, particularly in patients without any prior surgery in inguinal and scrotal region.
  • Daugaard reported 2% incidence of inguinal metastasis for stage 1 testicular cancer in 5-year period.
  • We reported a case of inguinal metastasis from residual testicular cancer with a large size of mass.
  • For this case, surgical treatment of residual tumor excision had been performed prior to the chemotherapy considering a quite large size of tumor mass, which may easily bleed and causing anemia to the patient.
  • Furthermore, we considered that chemotherapy treatment prior to surgical excision will only provide partial effect on the tumor.
  • After the surgery, a 4-cycle combined chemotherapy was administered despite the delay of chemotherapy treatment resulting in residual mass in inguinal region.
  • In fact, the post-surgical chemotherapy treatment in this case has demonstrated relatively good response.
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Fatal Outcome. Groin. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Neoplasm, Residual. Skin Transplantation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19258677.001).
  • [ISSN] 0125-9326
  • [Journal-full-title] Acta medica Indonesiana
  • [ISO-abbreviation] Acta Med Indones
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Indonesia
  •  go-up   go-down


2. Kitahara K, Hori J, Tokumitsu M, Saga Y, Hashimoto H, Kaneko S, Yachiku S: [Retroperitoneal germ cell tumor with testicular calcification indicating tiny testicular origin: consideration of the origin of retroperitoneal germ cell tumors: report of two cases]. Hinyokika Kiyo; 2003 May;49(5):291-5
MedlinePlus Health Information. consumer health - Testicular Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two cases of germ cell neoplasm retrospectively considered to have been of testicular origin are reported. Case 1.
  • After multidisciplinary treatment, a region of calcification was detected in the left testis on scrotal sonography and left high inguinal orchiectomy was performed. Case 2.
  • After chemotherapy, high inguinal orchiectomy and retroperitoneal lymphadenectomy were simultaneously performed.
  • Pathologic evaluation of these testicular specimens revealed calcification and a fibrous scar in correspondence with the clinical diagnosis.
  • These changes were considered as scars of the primary testicular tumor due to burned-out tumor or the result of reaction to chemotherapy.
  • [MeSH-minor] Adult. Brain Neoplasms / pathology. Diagnosis, Differential. Endodermal Sinus Tumor. Humans. Liver Neoplasms / pathology. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12822460.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 15
  •  go-up   go-down


3. Cabanas J, Gomes da Silva R, Goldstein P, Verghese M, Sugarbaker PH: Recurrence of pseudomyxoma peritonei within the inguinal canal. Tumori; 2005 Nov-Dec;91(6):481-6
Genetic Alliance. consumer health - Pseudomyxoma peritonei.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of pseudomyxoma peritonei within the inguinal canal.
  • AIM AND BACKGROUND: Tumor appearing in an inguinal hernia sac indicates widespread carcinomatosis with ascites.
  • Recurrence of pseudomyxoma peritonei within the inguinal region was previously reported in only a single patient.
  • We present five patients with a recurrence of pseudomyxoma peritonei tumor nodules in the inguinal region following cytoreductive surgery and attempt to understand the etiology of this treatment failure.
  • METHODS AND STUDY DESIGN: From a database of 910 patients with mucinous appendiceal tumors with peritoneal dissemination who had definitive treatment, five patients who had disease recurrence within the inguinal region were identified.
  • RESULTS: Five patients with ages ranging 39 to 67 years had a mucinous tumor in the inguinal region as a recurrence after a previous cytoreductive surgery combined with perioperative intraperitoneal chemotherapy.
  • One of them had separate recurrence in both right and left inguinal regions.
  • None have evidence of a recurrence of an inguinal hernia despite the lack of formal repair.
  • CONCLUSION: At the time of initial cytoreductive surgery the surgeon should be aware of the inguinal region as a possible site of relapse.
  • Inguinal recurrences should be removed with clear margins even if orchiectomy is required.
  • [MeSH-major] Adenocarcinoma, Mucinous. Hernia, Inguinal / etiology. Inguinal Canal. Neoplasm Recurrence, Local. Peritoneal Neoplasms. Pseudomyxoma Peritonei
  • [MeSH-minor] Adult. Aged. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16457146.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Grabenbauer GG, Kessler H, Matzel KE, Sauer R, Hohenberger W, Schneider IH: Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients. Dis Colon Rectum; 2005 Sep;48(9):1742-51
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
  • PATIENTS AND METHODS: Between 1985 and 2001, a total of 101 patients with anal carcinoma were registered for curative treatment, of whom 77 had involvement of the anal canal alone, 10 cases had extension into the perianal skin, and 14 patients had pure anal margin tumors.
  • Radiation treatment was directed to the primary tumor region and to the inguinal, perirectal, and internal iliac nodes using a three-field to four-field box technique with 10MV photons up to a total dose of 5040 cGy.
  • All patients were scheduled for simultaneous chemotherapy with two cycles of 5-fluorouracil at a dose of 1000 mg/m (2)/day as 120 hours of continuous intravenous infusion on Days 1 to 5 and 29 to 33 and mitomycin C at 10 mg/m (2)/day on Days 1 and 29.
  • Median follow-up time was was 7.5 (range, 1-16) years.
  • Following multivariate analysis, tumor location (anal canal vs. anal margin, P = 0.02), age (P = 0.003), and dose intensity of chemotherapy (< or =75 percent vs. >75 percent, P = 0.03) remained independent significant factors for overall survival.
  • CONCLUSIONS: With colostomy-free survival rates around 85 percent, long-term treatment results for anal canal carcinoma have reached a satisfactory level.
  • However, patients with larger lesions of the perianal skin are at high risk for locoregional recurrence and possible treatment intensification in this subgroup seems desirable.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991058.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Takeshita H, Yonese J, Fujii Y, Kawakami S, Komai Y, Ohkubo Y, Yamamoto S, Ishikawa Y, Seto Y, Ohyama S, Fukui I: Successful 2-year-long remission following repeated salvage surgery in a patient with chemotherapy-resistant metastatic nonseminomatous germ cell tumor. Int J Clin Oncol; 2007 Dec;12(6):485-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful 2-year-long remission following repeated salvage surgery in a patient with chemotherapy-resistant metastatic nonseminomatous germ cell tumor.
  • A 34 year-old man with a diagnosis of nonseminomatous testicular cancer with retroperitoneal lymph node metastasis (T1N3M0S2, stage IIIb; intermediate prognosis, made after right inguinal orchiectomy was performed) was referred to our hospital after having had a total of eight courses of systemic chemotherapy and external-beam radiotherapy to the retroperitoneal region in the previous 1 year.
  • Two courses of paclitaxel, etoposide, and cisplatin combined chemotherapy (TEP; paclitaxel 120 mg/m(2) day 1, etoposide 80 mg/m(2) days 2-5, cisplatin 20 mg/m(2) days 2-5) failed to normalize the AFP level.
  • During the following 2 years he underwent salvage surgery four times; infrarenal retroperitoneal lymph node dissection (RPLND), left neck lymph node dissection, thoracic duct excision, and suprarenal RPLND.
  • The present case suggests that repeated salvage surgery may be beneficial in selected patients with a chemotherapy-resistant metastatic germ cell tumor.
  • [MeSH-minor] Adult. Antinematodal Agents / therapeutic use. Drug Resistance, Neoplasm. Humans. Lymphatic Metastasis. Male. Remission Induction. Reoperation. Salvage Therapy. Treatment Outcome. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Nonseminomatous germ cell tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Clin Oncol. 2010 Oct;15(5):528-9 [20686911.001]
  • [Cites] J Urol. 2000 Aug;164(2):381-4 [10893590.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1859-63 [11919245.001]
  • [Cites] Cancer. 1992 Nov 1;70(9):2354-7 [1382832.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):324-9 [8381163.001]
  • (PMID = 18071871.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antinematodal Agents; 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


6. Cahalane AK, Payne S, Barber LG, Duda LE, Henry CJ, Mauldin GE, Frimberger AE, Cotter SM, Moore AS: Prognostic factors for survival of dogs with inguinal and perineal mast cell tumors treated surgically with or without adjunctive treatment: 68 cases (1994-2002). J Am Vet Med Assoc; 2004 Aug 1;225(3):401-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for survival of dogs with inguinal and perineal mast cell tumors treated surgically with or without adjunctive treatment: 68 cases (1994-2002).
  • OBJECTIVE: To determine the prognostic factors for survival and tumor recurrence in dogs with cutaneous mast cell tumors (MCTs) in the perineal and inguinal regions treated surgically with or without adjunctive radiation therapy, chemotherapy, or both.
  • PROCEDURE: Medical records of dogs with histologically confirmed MCTs in the perineal region, inguinal region, or both treated surgically with or without adjunctive radiation therapy, chemotherapy, or both were reviewed.
  • Median survival time was 1,111 days (mean, 1,223 days), and 1- and 2-year survival rates were 79% and 61%, respectively.
  • Factors that negatively influenced survival time were age at diagnosis, tumor recurrence, and treatment with lomustine.
  • CONCLUSIONS AND CLINICAL RELEVANCE: Results indicated that dogs with MCTs in the inguinal and perineal regions, if appropriately treated, may have survival times and tumor-free intervals similar to dogs with MCTs in other locations.
  • [MeSH-minor] Animals. Chemotherapy, Adjuvant / veterinary. Disease-Free Survival. Dogs. Female. Groin. Male. Neoplasm Recurrence, Local / veterinary. Perineum. Prognosis. Radiotherapy, Adjuvant / veterinary. Retrospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15328716.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Adam Z, Veselý K, Krejcí M, Pour L, Fakan F, Soumarová R, Neubauer J, Vanícek J, Cerný J, Kren L, Bolcák K, Smardová L, Hájek R, Mayer J: [Interdigitating dendritic cell sarcoma of lower extremities resistant to high dose chemotherapy BEAM with peripheral blood stem cell transplantation]. Vnitr Lek; 2009 Feb;55(2):147-57
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interdigitating dendritic cell sarcoma of lower extremities resistant to high dose chemotherapy BEAM with peripheral blood stem cell transplantation].
  • Interdigitating dendritic cell sarcoma is a rare neoplasm forming part of the group of malignancies derived from histocytic cell line.
  • The pathological process affected proximal tibial epiphysis and adjacent soft tissues.
  • The first FDG-PET examination performed in the process of determining the clinical stage of the disease showed a high activity in the site of primary tumour (SUV 7.71) and in the site of regional inguinal node (SUV 4.25).
  • Histological examination of a diagnostic excision specimen of the tumour in the tibia and the extirpated enlarged regional nodes in the left groin led to the diagnosis of interdigitating dendritic cell sarcoma.
  • The diagnosis was confirmed pathologically by another two centres in the Czech Republic and, due to the unusual nature of the diagnosis, also in Regensburg, Germany.
  • Treatment started with chemotherapy, applied to patients with aggressive lymphomas in the framework of clinical studies, i.e. a combination of MegaCHOP.
  • MegaCHOP therapy was therefore discontinued after the 4 cycles.
  • Subsequently, we referred the patient for a high-dose chemotherapy with autologous bone marrow transplantation, similarly to aggressive lymphomas.
  • The collection of blood producing stem cells from peripheral blood was successfully performed after ESHAP chemotherapy.
  • A verificatoin FDG-PET examination was performed before high-dose chemotherapy.
  • One month after ESHAP chemotherapy, BEAM high-dose chemotherapy with autologous transplantation of blood forming tissue was performed.
  • High-dose chemotherapy was followed up by radiotherapy targeted on the primary tumour in the crus (70 Gy).
  • The examination showed a continuing higher activity in the region of the primary tumour (SUV 2.69) and a new centre of activity was detected in the left inguinal nodes region (SUV4.09).
  • The activity corresponded to the presence of viable tumour tissue in the primary nidus and new metastases in inguinal nodes, without proofs of further proliferation at the time.
  • Histological examination showed affection of the node by the same type of tumour, i.e. a continuing activity of the disease despite chemotherapy.
  • Due to suspected continuation of viable tumour in the crus judging by the intensity of accumulation of FDG-PET and the proof of a new affection of regional nodes, surgical treatment was preferred after the failure of chemotherapy.
  • After the removal of inguinal nodes, left knee joint exarticulation was performed.
  • This was followed by regional inguinal node region radiotherapy (56 Gy).
  • The last fourth PET-CT examination carried out 4 months after the radiation therapy of the inguinal region showed massive dissemination into the region ofileac and paraaortic nodes (lymphadenopathy up to 6 cm in diameter) with an activity of 5.9 to 6.73 SUV units.
  • Currently, we test the sensitiveness of the disease to 2-chlordeoxyadenosin and look for additional therapeutic options.
  • To our knowledge, the above description is the first documented case of interdigitating dendritic cell sarcoma located in the tibia and crus soft tissue.
  • We have not found any description of high-dose therapy supported by autologous transplantation of blood-forming tissue for this type of tumour in relevant literature.
  • In this case, we record chemoresistance to high-dose chemotherapy and certain radiosensitivty of the tumour at the same time.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Dendritic Cell Sarcoma, Interdigitating / therapy. Drug Resistance, Neoplasm. Leg. Peripheral Blood Stem Cell Transplantation. Soft Tissue Neoplasms / therapy. Tibia
  • [MeSH-minor] Adult. Carmustine / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Humans. Male. Melphalan / administration & dosage. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19348397.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM regimen
  • [Number-of-references] 69
  •  go-up   go-down


8. Mitchell SE, Mendenhall WM, Zlotecki RA, Carroll RR: Squamous cell carcinoma of the anal canal. Int J Radiat Oncol Biol Phys; 2001 Mar 15;49(4):1007-13
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To report the results of primary radiotherapy for treatment of anal canal carcinoma from the University of Florida series and review issues related to treatment of this disease.
  • METHODS AND MATERIALS: Forty-nine patients were treated with primary radiation therapy (RT) for cure.
  • After 1990, patients with lesions of at least 3 cm also received chemotherapy with fluorouracil (1000 mg/m(2)) plus cisplatin (100 mg/m(2)) or mitomycin (10-15 mg/m(2)) if medically fit (n = 26).
  • RT was delivered with a 4-field box technique to deliver 45 Gy in 25 fractions.
  • The inguinal nodes were treated daily using electrons to supplement the dose in that region to a total dose of 45 Gy if clinically negative or about 60 Gy if involved.
  • A 10- to 15-Gy boost was delivered using interstitial iridium 192 implant (n = 32), en face (60)Co field (n = 5), or external-beam photon fields (n = 11).
  • There was an improvement in local control with the addition of chemotherapy in more advanced disease, but it was not significant.
  • There was an increase in acute toxicity with the addition of chemotherapy (12% > or = Grade 4) but not long-term toxicity.
  • Late toxicity requiring colostomy occurred in 6% of patients and consisted of soft tissue necrosis.
  • CONCLUSIONS: The majority of patients with anal canal carcinoma can be treated with curative intent using a sphincter-sparing approach of radiation with or without chemotherapy even with advanced disease.
  • With the addition of chemotherapy to radiation, there is an increased risk of acute toxicity and about 1-2% incidence of toxic death.
  • Smaller tumors (T1 and early T2) probably do not require the addition of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / physiology. Analysis of Variance. Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Radiotherapy Dosage. Salvage Therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11240241.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Otto T, Suhr J, Krege S, Rübben H: [Therapy of advanced penis carcinoma]. Urologe A; 2003 Nov;42(11):1466-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy of advanced penis carcinoma].
  • [Transliterated title] Die Therapie des fortgeschrittenen Peniskarzinoms.
  • Skin infiltration and locoregional lymph node extension in metastatic penile cancer leads to destruction in the inguinal and perineal region.
  • The obligatorily superinfected defects require tension-free and extended coverage with immediate myocutaneous flaps after surgical resection.
  • Data concerning a prospective study for neoadjuvant chemotherapy with CMB followed by surgical tumor resection with immediate myocutaneous flap reconstruction are presented.
  • In 15 patients (median age: 69.7 years) suffering from squamous cell carcinoma of the penis (Tx, N3, M1 cutis), a surgical excision of the tumor was performed after neoadjuvant chemotherapy (median:2.4 cycles) and antibiotic pretreatment.
  • An extended (up to 45x30 cm) tension-free coverage of groin defects was performed in two patients with a unilateral M. tensor fasciae latae flap (TFL) and in eight patients with a bilateral TFL.
  • Of 31 myocutaneous pedicle flaps, 2 developed distant necrosis of the flap, in which one GMFL and one TFL were affected.
  • The covering of groin defects by the use of myocutaneous flaps, such as the M. tensor fasciae latae, M. rectus abdominis, and M. gluteus maximus flap, is a method of first choice in the primary treatment of even bacterially contaminated wounds or after radiation therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Neoadjuvant Therapy. Penile Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibiotic Prophylaxis. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Graft Survival / drug effects. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Microsurgery. Neoplasm Invasiveness. Neoplasm Staging. Skin / pathology. Superinfection / prevention & control. Surgical Flaps / blood supply. Surgical Wound Infection / prevention & control. Suture Techniques. Treatment Outcome. Wound Healing / drug effects

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plast Reconstr Surg. 2001 Dec;108(7):1998-2005 [11743391.001]
  • [Cites] Br J Plast Surg. 1987 Sep;40(5):485-7 [3676574.001]
  • [Cites] Urologe A. 1997 Mar;36(2):157-61 [9199044.001]
  • [Cites] J Urol. 1999 Jun;161(6):1823-5 [10332445.001]
  • [Cites] J Urol. 1982 Sep;128(3):599-601 [7120574.001]
  • [Cites] Urol Int. 1998;61(4):243-6 [10364759.001]
  • [Cites] Br J Plast Surg. 1982 Oct;35(4):413-9 [7139168.001]
  • [Cites] Urol Clin North Am. 1992 May;19(2):333-8 [1374199.001]
  • [Cites] J Urol. 2001 Oct;166(4):1384-5 [11547082.001]
  • [Cites] J Urol. 2003 Jan;169(1):118-20 [12478117.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1983 Jul;74(7):1113-21 [6663941.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1997 Dec;356(6):769-76 [9453463.001]
  • (PMID = 14624345.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


10. Coloma del Peso A, Arellano Gañán R, Garrido Abad P, Fernández González I, Couñago Lorenzo F, Gómez-Ulla Astray J, Ortega Serrano MP, Bocardo Fajardo G, Rabadán Ruiz M, Pereira Sanz I: [Atypical lymphatic dissemination of a testicular tumor from a cryptorquid testicle]. Arch Esp Urol; 2009 Jun;62(5):389-92
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Diseminación linfática atípica de un tumor testicular sobre un testículo criptorquídico.
  • OBJECTIVES: Atypical lymphatic spread of germ cell tumors to inguinal lymph nodes has been reported mostly related to prior surgical involvement of the inguinoscrotal region, as in orchiopexy.
  • METHODS: A patient with cryptorchidism and failed orchiopexy in his childhood was diagnosed with a testicular neoplasm.
  • Inguinal orchiectomy was performed.
  • Patient was treated with adjuvant chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19721174.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


11. Ma YT, Ramachandra P, Spooner D: Case report: primary subcutaneous sacrococcygeal ependymoma: a case report and review of the literature. Br J Radiol; 2006 May;79(941):445-7
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority occur in the sacrococcygeal region.
  • Treatment is complete surgical resection.
  • Up to 20% metastasise, chiefly to the inguinal lymph glands, but pulmonary metastases are also reported.
  • Palliative chemotherapy has not been shown to be of any benefit.
  • [MeSH-major] Ependymoma / diagnosis. Neoplasm Recurrence, Local / diagnosis. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biomarkers / analysis. Female. Glial Fibrillary Acidic Protein / analysis. Humans. Ilium. Immunohistochemistry / methods. Lymphatic Metastasis. Magnetic Resonance Imaging. Radiotherapy, Adjuvant. Reoperation. S100 Proteins / analysis. Sacrococcygeal Region. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16632628.001).
  • [ISSN] 0007-1285
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Glial Fibrillary Acidic Protein; 0 / S100 Proteins; 0 / Vimentin
  • [Number-of-references] 12
  •  go-up   go-down


12. Gupta P, Singh U, Singh SK, Kapoor R, Gupta V, Das A: Bilateral symmetrical metastasis to all extraocular muscles from distant rhabdomyosarcoma. Orbit; 2010 Jun;29(3):146-8
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Rhabdomyosarcoma arising in the inguinal region has high potential of metastasis.
  • The common sites for spread from inguinal region include regional lymph nodes, lungs, bone marrow and bone cortex.
  • This case report describes a patient with inguinal rhabdomyosarcoma, which metastasized to both orbits to all the extraocular muscles.
  • CASE REPORT: A 14-year-old male patient presented with inguinal mass involving the scrotum.
  • The patient underwent high inguinal orchiectomy with hemiscrotectomy for the mass and histopathology revealed rhabdomyosarcoma.
  • After 2 weeks of initial surgery the patient developed bilateral axial proptosis and radiological imaging revealed bilateral extraocular muscle thickening involving all the extraocular muscles.
  • Metastasis from inguinal rhabdomyosarcoma to extraocular muscles bilaterally involving all the muscles has not been reported in the literature.
  • The present report describes one such patient with favorable initial response to chemotherapy and muscle thickness reverting to normal.
  • Metastasis from a distant site should be considered in differential diagnosis when evaluating a patient with bilateral enlargement of all extraocular muscles.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Follow-Up Studies. Humans. Male. Neoplasm Invasiveness / pathology. Neoplasm Staging. Oculomotor Muscles. Orbital Neoplasms / drug therapy. Orbital Neoplasms / secondary. Orchiectomy / methods. Risk Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20497080.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Kitamura K, Takeuchi J, Kanbe E, Oka H, Saiki M, Aikawa S, Kura Y, Hatta Y, Yamazaki T, Ito T, Sawada U, Horie T: [Multiple myeloma of the IgD-lambda type invading CNS]. Rinsho Ketsueki; 2004 Oct;45(10):1124-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple myeloma of the IgD-lambda type invading CNS].
  • A 52-year-old woman was admitted to the gynecological department of our hospital on July 29, 2002 because of a right lower abdominal mass.
  • She has been suffering from pain in the right leg and inguinal area for a month before coming to the hospital.
  • A bone marrow examination showed 63.8% of plasma cells and serum immunoelectrophoresis showed M-protein of the IgD-lambda type.
  • VAD therapy was started from August 22.
  • Although the plasma cells in the bone marrow almost disappeared, the right lower abdominal mass remained and a new mass appeared on the right frontal chest wall after two courses of the treatment.
  • Combination chemotherapy with vincristine, ranimustine, melphalan, and dexamethasone (ROAD) was started on November 1.
  • This was followed with thalidomide and radiation therapy of the right inguinal region was added.
  • The plasma cells disappeared after the 6th intrathecal injection with MTX and prednisolone and the chemotherapy was resumed.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / therapy. Multiple Myeloma / pathology. Multiple Myeloma / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers / analysis. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Drug Therapy, Combination. Fatal Outcome. Female. Humans. Immunoglobulin D / blood. Injections, Spinal. Interferon-alpha / administration & dosage. Melphalan / administration & dosage. Methotrexate / administration & dosage. Middle Aged. Myeloma Proteins / analysis. Neoplasm Invasiveness. Nitrosourea Compounds / administration & dosage. Prednisolone / administration & dosage. Radiotherapy, Adjuvant. Thalidomide / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553049.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Immunoglobulin D; 0 / Interferon-alpha; 0 / Myeloma Proteins; 0 / Nitrosourea Compounds; 0 / multiple myeloma M-proteins; 4Z8R6ORS6L / Thalidomide; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 9PHQ9Y1OLM / Prednisolone; Q41OR9510P / Melphalan; YL5FZ2Y5U1 / Methotrexate; ROAD-IN protocol; VAD protocol
  •  go-up   go-down


14. Hamanishi J, Higuchi T, Mandai M, Fukuhara K, An M, Nakayama T, Takakura K, Fujii S: Intractable recurrent cervical cancer with pelvic bone involvement successfully treated with external hemipelvectomy. J Obstet Gynaecol Res; 2008 Feb;34(1):112-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 38-year-old woman who had undergone conization for stage Ia1 cervical cancer six years earlier had severe right inguinal pain.
  • A large multicystic recurrent tumor was identified in the right obturator region.
  • After chemotherapy and chemoradiation, the tumor regressed, but soon relapsed.
  • We performed right external hemipelvectomy with amputation of the right lower extremity, right iliac wing and ischiopubic bone.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Neoplasm Recurrence, Local / diagnosis. Pelvic Bones / surgery. Pelvic Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Combined Modality Therapy. Conization. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis


15. Ferrigno R, Nakamura RA, Dos Santos Novaes PE, Pellizzon AC, Maia MA, Fogarolli RC, Salvajoli JV, Filho WJ, Lopes A: Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys; 2005 Mar 15;61(4):1136-42
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
  • PURPOSE: This retrospective analysis reports the results on patients with anal canal carcinoma treated by combined radiotherapy and chemotherapy.
  • The median dose of RT at the whole pelvis and at the primary tumor was 45 Gy and 55 Gy, respectively.
  • Chemotherapy was carried out during the first and last 4 days of RT with continuous infusion of 5-fluorouracil (1000 mg/m(2)) and bolus mitomycin C (10 mg/m(2)).
  • Median overall treatment time was 51 days (range, 30-129 days).
  • Thirty-four patients (79%) did not receive elective RT at the inguinal region.
  • Patient's age, tumor stage, overall treatment time, and RT dose at primary tumor were variables analyzed for survival and local control.
  • RESULTS: Median follow-up time was 42 months (range, 4-116 months).
  • According to the RT dose, local control was higher among patients who received more than 50 Gy at primary tumor (86.5% vs. 34%, p = 0.012).
  • Inguinal failure was observed in 5 patients (15%) who did not receive inguinal elective RT.
  • Temporary interruption of the treatment as a result of acute toxicity was necessary in 12 patients (28%).
  • Four patients developed mild chronic complications.
  • CONCLUSIONS: This analysis suggests that the treatment scheme employed was effective for anal sphincter preservation and local control; however, the incidence of distant metastases was relatively high.
  • Local control was higher in patients treated with doses of more than 50 Gy at primary tumor.
  • The high incidence of inguinal failure implies the need for elective RT in this region.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Recurrence, Local / surgery. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15752894.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Iinuma H, Okinaga K, Fukushima R, Inaba T, Iwasaki K, Arai T, Tamura J, Kumagai H: [Reduction of immunosuppression and shift to Th1 response by tumor-DC (dendritic cells) fusion vaccine]. Gan To Kagaku Ryoho; 2004 Oct;31(11):1640-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nine patients with advanced or recurrent gastrointestinal cancer that was unresponsive to standard surgical therapy and chemotherapy were enrolled in this study after informed consent was obtained.
  • The fusion vaccine was injected subcutaneously into the inguinal region four times every two weeks.
  • [MeSH-major] Antigens, Neoplasm / immunology. Cancer Vaccines. Dendritic Cells / immunology. Gastrointestinal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553669.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines
  •  go-up   go-down


17. Busby JE, Pettaway CA: What's new in the management of penile cancer? Curr Opin Urol; 2005 Sep;15(5):350-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This has led to little in the way of therapeutic advances in the last two decades.
  • Efforts have been made to minimize the use of disfiguring or morbid procedures in treating the primary tumor or managing the inguinal region.
  • In addition, new insights have been gained into multimodal therapy for treating metastatic disease.
  • We reviewed the literature published during the past two years to define the recent insights into the diagnosis and management of penile cancer.
  • To improve diagnosis and staging, new modifications in imaging have been developed including magnetic resonance imaging with artificial erection.
  • Organ-sparing treatments using laser ablation and reconstructive procedures to preserve glans or phallus length have also been developed.
  • Systemic chemotherapy regimens, including consolidative approaches with surgery or radiotherapy, are discussed for advanced penile cancer.
  • Recent literature provides information that will aid urologists in (1) minimizing the need for disfiguring treatment of penile tumors in some patients and (2) reducing the number of unnecessary inguinal staging procedures in others.
  • Novel systemic therapies that generate durable responses tested in multi-institutional treatment trials are needed.
  • [MeSH-major] Penile Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Diagnostic Imaging. Humans. Male. Neoplasm Staging. Risk Factors. SEER Program. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16093861.001).
  • [ISSN] 0963-0643
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 49
  •  go-up   go-down


18. Perera D, Pathma-Nathan N, Rabbitt P, Hewett P, Rieger N: Sentinel node biopsy for squamous-cell carcinoma of the anus and anal margin. Dis Colon Rectum; 2003 Aug;46(8):1027-9; discussion 1030-1
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They are best treated by combination of chemotherapy and radiotherapy.
  • T1 and T2 tumors in this regime do not receive radiotherapy to the inguinal regions despite approximately 5 to 10 percent incidence of inguinal lymph node involvement.
  • If the nodal status of the inguinal region could be accurately assessed, then a more tailored radiotherapy regime may be given.
  • This article describes a novel method of assessment of the status of the inguinal lymph nodes in patients.
  • RESULTS: This procedure was performed on 12 patients.
  • The sentinel node was localized to the inguinal region and removed in eight of these patients.
  • CONCLUSION: We advocate that this as a safe technique for detecting metastatic disease in the inguinal nodes in patients with anal squamous-cell carcinoma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12907894.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Rabbitt P, Pathma-Nathan N, Collinson T, Hewett P, Rieger N: Sentinel lymph node biopsy for squamous cell carcinoma of the anal canal. ANZ J Surg; 2002 Sep;72(9):651-4
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The current Trans-Tasman Radiation Oncology Group (TROG) protocol for T1 and T2 anal cancers is combination chemotherapy and radiotherapy excluding the inguinal region from the field.
  • Several centres worldwide irradiate both inguinal regions as there is a small incidence of involvement with early stage tumours.
  • The presence of inguinal lymph node metastases is not accurately detected using clinical and most radiological assessment modalities.
  • We have developed a method of sampling the sentinel node in the groin using established node mapping techniques.
  • A groin sentinel node was identified and removed in three of these, with pathological assessment excluding metastatic disease in the inguinal region.
  • CONCLUSIONS: The application of this effective technique will allow accurate staging of anal cancers to better plan future treatment regimes.
  • [MeSH-minor] Aged. Female. Humans. Lymphatic Metastasis / pathology. Neoplasm Staging

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12269917.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


20. Choo R, Sandler H, Warde P, Hruby G, DeBoer G: Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States. Can J Urol; 2002 Apr;9(2):1479-85
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Almost all would perform chest x-ray (99%) and CT scan of abdomen and pelvis (100%) as staging investigation following radical inguinal orchiectomy.
  • Among four management options: (1. surveillance, 2. radiotherapy (RT) to the para-aortic region, 3.
  • RT to the para-aortic and ipsilateral pelvis ('dog-leg'), 4. single-agent chemotherapy), the order of first preference was option 1 (44%), 2 (42%), and 3 (14%) for patients who wish to preserve fertility.
  • The commonest dose-fractionation schedule was 25 Gy/20 fractions (68%).
  • Others included 25 Gy/15 f (15%), and 25.5 Gy/17 f (4%).
  • Forty-five percent chose the para-aortic region, while 53% used the 'dog-leg' as RT volume.
  • Twenty-nine percent reduced RT volume from the 'dog-leg' to the para-aortic region as the result of MRC Phase III study published in 1999.
  • [MeSH-major] Practice Patterns, Physicians' / statistics & numerical data. Seminoma / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Canada. Data Collection / methods. Dose Fractionation. Humans. Male. Neoplasm Staging. Radiation Oncology. Radiotherapy, Adjuvant. Surveys and Questionnaires. United States

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Can J Urol. 2002 Apr;9(2):1476 [12010591.001]
  • (PMID = 12010592.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


21. Mistrangelo M, Mobiglia A, Cassoni P, Castellano I, Maass J, Martina MC, Bellò M, Mussa A: [Verrucous carcinoma of the anus or Buschke-Lowenstein tumor of the anus: staging and treatment. Report of 3 cases]. Suppl Tumori; 2005 May-Jun;4(3):S29-30
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Verrucous carcinoma of the anus or Buschke-Lowenstein tumor of the anus: staging and treatment. Report of 3 cases].
  • These are slow-growing, expansive, cauliflower-like, destructive lesions that could propagate to vulvar and vaginal region, rectum and bladder.
  • In two cases immunodeficiency was evidentiated (HIV in one case and ciclosporin treatment in the second one).
  • In another case a lesion in sacral region was observed.
  • All patients were studied with anoproctoscopy, CT scan, pelvic magnetic resonance and lymphoscintigraphy for following biopsy of inguinal sentinel node for potential malignancy.
  • All patients were submitted to extensive local surgical treatment.
  • All inguinal nodes revealed negative to definitive histological exam, that confirmed the diagnosis of Buschke Lowenstein tumor of the primary lesion.
  • Local surgery with elettrocautery or laser is the first treatment of choice, even if abdominoperineal amputation sec.
  • Others treatments proposed are radiotherapy, chemotherapy, interferon, iniquimod and so on.
  • Other studies are requested to value the best treatment.
  • [MeSH-minor] Adult. Humans. Male. Neoplasm Staging

  • Genetic Alliance. consumer health - Buschke Lowenstein Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437884.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


22. Neumann I, Strauss HG, Buchmann J, Koelbl H: Ectopic lobular breast cancer of the vulva. Anticancer Res; 2000 Nov-Dec;20(6C):4805-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Primary breast cancer of the vulvar region is a rare tumor entity.
  • The woman with elevated CA 15-3 and CEA markers underwent local wide excision of the tumor and bilateral inguinal lymphonodectomy, adjuvant anthracycline containing chemotherapy and locoregional irradiation including both inguinal regions and subsequent endocrine therapy with tamoxifen.
  • Original tissue of the breast adjacent to the malignant vulvar transformation was lacking.
  • CONCLUSION: Due to the rare occurrence, we are not able to give general guidelines for the treatment of ectopic breast cancer.
  • However, adjustment of treatment to the therapeutic recommendations for orthotopic breast cancer seems reasonable and effective.
  • [MeSH-minor] Choristoma. Female. Humans. Lymph Node Excision. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11205223.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


23. Bhalla RK, Jones TM, Errington D, Roland NJ: Metastatic testicular seminoma--a case report. Auris Nasus Larynx; 2002 Apr;29(2):219-22
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The medical history revealed that 2 years earlier the patient had been diagnosed with a testicular seminoma for which he underwent a right inguinal orchidectomy and abdominal radiotherapy.
  • CT scan highlighted a 6 cm para-laryngeal mass, of mixed attenuation, with an adjacent region of inflammation.
  • He is currently undergoing chemotherapy, and is responding well.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / secondary. Seminoma / secondary. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Disease Progression. Humans. Male. Neoplasm Staging

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11893462.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


24. Yap OW, Kapp DS, Teng NN, Husain A: Intraoperative radiation therapy in recurrent ovarian cancer. Int J Radiat Oncol Biol Phys; 2005 Nov 15;63(4):1114-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative radiation therapy in recurrent ovarian cancer.
  • PURPOSE: To evaluate disease outcomes and complications in patients with recurrent ovarian cancer treated with cytoreductive surgery and intraoperative radiation therapy (IORT).
  • METHODS AND MATERIALS: A retrospective study of 24 consecutive patients with ovarian carcinoma who underwent secondary cytoreduction and intraoperative radiation therapy at our institution between 1994 and 2002 was conducted.
  • Outcomes measures were local control of disease, progression-free interval, overall survival, and treatment-related complications.
  • Additional treatment at the time of and after IORT included whole abdominopelvic radiation, 9; pelvic or locoregional radiation, 5; chemotherapy, 6; and no adjuvant treatment, 2.
  • IORT doses ranged from 9-14 Gy (median, 12 Gy).
  • The anatomic sites treated were pelvis (sidewalls, vaginal cuff, presacral area, anterior pubis), para-aortic and paracaval lymph node beds, inguinal region, or porta hepatitis.
  • Five patients recurred within the radiation fields for a locoregional relapse rate of 32% and 12 patients recurred at distant sites with a median time to recurrence of 13.7 months.
  • Five-year overall survival was 22% with a median survival of 26 months from time of IORT.
  • Nine patients (41%) experienced Grade 3 toxicities from their treatments.
  • [MeSH-major] Neoplasm Recurrence, Local / radiotherapy. Ovarian Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15964710.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement